These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36947724)

  • 1. Targeting
    Phadke MS; Smalley KSM
    J Clin Oncol; 2023 May; 41(14):2661-2664. PubMed ID: 36947724
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of two different mutations in codon 12 of NRAS gene in ulcerated penile mucosal nodular malignant melanoma pT4b of the 90-year-old man in perspective of targeted therapy of NRAS-mutated advanced melanomas.
    Wincewicz A; Hińcza K; Ossoliński K; Ossolińska A; Ossoliński T; Kopczynski J; Góźdź S; Kowalik A
    Dermatol Ther; 2020 Nov; 33(6):e14115. PubMed ID: 32735072
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
    Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
    J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gene abnormalities in melanoma and signal transduction antagonists].
    Takada M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 7. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
    Del Regno L; Louveau B; Battistella M; Sadoux A; Baroudjian B; Delyon J; Serror K; Allayous C; Lebbe C; Mourah S; Jouenne F
    Br J Dermatol; 2020 May; 182(5):1281-1283. PubMed ID: 31675434
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.
    Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J;
    J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma.
    Sheen YS; Chu CY
    Br J Dermatol; 2021 Mar; 184(3):390-391. PubMed ID: 33448329
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.
    Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
    Arozarena I; Goicoechea I; Erice O; Ferguson J; Margison GP; Wellbrock C
    Mol Cancer; 2014 Jun; 13():154. PubMed ID: 24941944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.